Waldenström′s macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection
Open Access
- 10 October 2017
- journal article
- review article
- Published by Wiley in European Journal of Haematology
- Vol. 99 (6) , 469-478
Abstract
Waldenström′s macroglobulinemia (WM) is a complex disease characterized by apparent morphological heterogeneity within the malignant clonal cells representing a continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. At the molecular level, the neoplastic B cell–derived clone has undergone somatic hypermutation, but not isotype switching, and retains the capability of plasmacytic differentiation. Although by classical definition, WM is formed by monoclonal expansion, long‐lived clonal B lymphocytes are of heterogeneous origin. Even more, according to current opinion, plasma cells also conform certain population with pathogenic and clinical significance. In this article, we review the recent advances in the WM clonal architecture, briefly describe B‐cell development during which the molecular changes lead to the malignant transformation and mainly focus on differences between two principal B‐lineage clones, including analysis of their genome and transcriptome profiles, as well as immunophenotype features. We assume that the correct identification of a number of specific immunophenotypic molecular and expression alterations leading to proper aberrant clone detection can help to guide patient monitoring throughout treatment and successfully implement therapy strategies directed against both B‐ and plasma cell tumor WM clones.Keywords
Funding Information
- Ministerstvo Zdravotnictví Ceské Republiky (RVO ‐ FNOs/2015)
- Ministerstvo Školství, Mládeže a Tělovýchovy (SGS09/LF/2016‐2017)
This publication has 70 references indexed in Scilit:
- Waldenström Macroglobulinemia: Clinical and Immunological Aspects, Natural History, Cell of Origin, and Emerging Mouse ModelsISRN Hematology, 2013
- Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasmsBlood, 2013
- Nuclear Protein Dysregulation in Lymphoplasmacytic Lymphoma/Waldenström MacroglobulinemiaAmerican Journal of Clinical Pathology, 2013
- Analysis of the coding genome of diffuse large B-cell lymphomaNature Genetics, 2011
- Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenström macroglobulinaemiaJournal of Clinical Pathology, 2011
- Reversing pathological neural activity using targeted plasticityNature, 2011
- Bach2 represses plasma cell gene regulatory network in B cells to promote antibody class switchThe EMBO Journal, 2010
- Pathophysiology of Waldenstrom's macroglobulinemiaHaematologica, 2010
- microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemiaBlood, 2009
- Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myelomaBlood, 2006